New AI-Driven Collaboration Targets Cerebral Hemorrhage Treatment

Qanatpharma, the Zuse Institute Berlin, Enamine, and Proteros biostructures have announced an innovative collaboration aimed at developing a new therapy for delayed cerebral ischemia, a common complication following subarachnoid hemorrhage. This international effort leverages generative AI to accelerate early-stage drug discovery.

The collaboration focuses on a specific protein target that regulates cerebrovascular resistance. The partners will integrate computational models, medicinal chemistry, and structural biology, utilizing Enamine's vast compound libraries and Proteros's drug discovery platform to develop novel therapeutics.

This initiative addresses the unmet medical need for effective treatments, as current options like Nimodipine show limited efficacy. The collaboration has progressed to compound screening and will advance to in vitro studies later in 2025, setting a precedent for AI in medical research.